A Karytinos, A Ingham - Pharmaceutical Patent Analyst, 2015 - Taylor & Francis
Editorial Karytinos & Ingham skew this trend. What is less likely to change is the tendency of
big pharma companies to partner with, or acquire biotechnology IP from small, innovation …